Education
About Us
Working with TipRanks
Follow Us
Alkermes plc (ALKS)
NASDAQ:ALKS
ALKS Stock Chart & Stats
$33.52
-$0.20(-0.70%)
At close: 4:00 PM EST
$33.52
-$0.20(-0.70%)
Day’s Range― - ―
52-Week Range$25.17 - $36.45
Previous CloseN/A
Volume176.14K
Average Volume (3M)1.79M
Market Cap
$5.47B
Enterprise Value$4.99B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$71.60M
Price to Earnings (P/E)16.6
Beta0.68
Next Earnings
Feb 12, 2026EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.68
Shares Outstanding165,117,510
10 Day Avg. Volume2,292,329
30 Day Avg. Volume1,794,369
Financial Highlights & Ratios
PEG Ratio3.47
Price to Book (P/B)3.25
Price to Sales (P/S)3.05
P/FCF Ratio11.73
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue3.28
Enterprise Value/Gross Profit3.82
Enterprise Value/Ebitda11.46
Forecast
1Y Price Target
$46.17Price Target Upside37.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)1.72
Revenue Forecast (FY)$1.77B
Bulls Say, Bears Say
Bulls Say
Acquisition And Commercial ExpansionAcquisition of Avadel brings Lumryz into the portfolio, adding a growing NT1/NT2 product that is expected to be accretive and strengthen a first-mover commercial position in the orexin agonist market.
Clinical Trial ResultsPositive VIBRANCE-2 Phase 2 topline showed alixorexton met dual primary endpoints in NT2, supporting advancement to a pivotal program and positioning the drug as the first oral orexin-2 to demonstrate randomized Phase 2 efficacy in that indication.
Safety And Dosing FlexibilityFavorable safety findings in the study suggest dosing can be increased or split in later trials to potentially boost efficacy without clear new safety signals, giving the development program more options.
Bears Say
Clinical Timeline And Investor Sentiment RiskDelays and limited disclosure in the clinical program can trigger negative investor reactions and downward pressure on the share price as uncertainty around milestones increases.
Dosing Strategy And Patient Preference RiskAdopting split dosing erodes the once-nightly convenience advantage and could exacerbate insomnia-related adverse effects, risking weaker patient preference and slower uptake.
Efficacy Differentiation RiskPhase 2 effect sizes appeared comparable to existing therapies and did not deliver clear differentiation, leaving uncertainty about the drug's ability to command premium market share.
Alkermes News
ALKS FAQ
What was Alkermes plc’s price range in the past 12 months?
Alkermes plc lowest stock price was $25.16 and its highest was $36.45 in the past 12 months.
What is Alkermes plc’s market cap?
Alkermes plc’s market cap is $5.47B.
When is Alkermes plc’s upcoming earnings report date?
Alkermes plc’s upcoming earnings report date is Feb 12, 2026 which is in 14 days.
How were Alkermes plc’s earnings last quarter?
Alkermes plc released its earnings results on Oct 28, 2025. The company reported $0.684 earnings per share for the quarter, beating the consensus estimate of $0.369 by $0.315.
Is Alkermes plc overvalued?
According to Wall Street analysts Alkermes plc’s price is currently Undervalued.
Does Alkermes plc pay dividends?
Alkermes plc does not currently pay dividends.
What is Alkermes plc’s EPS estimate?
Alkermes plc’s EPS estimate is 0.42.
How many shares outstanding does Alkermes plc have?
Alkermes plc has 165,117,510 shares outstanding.
What happened to Alkermes plc’s price movement after its last earnings report?
Alkermes plc reported an EPS of $0.684 in its last earnings report, beating expectations of $0.369. Following the earnings report the stock price went up 4.307%.
Which hedge fund is a major shareholder of Alkermes plc?
Currently, no hedge funds are holding shares in ALKS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alkermes Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.17 (37.74% Upside)
$46.17 (37.74% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 886.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 18.0%
Last 30 Days ▲ 18.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.34%
12-Months-Change
Fundamentals
Return on Equity
22.35%
Trailing 12-Months
Asset Growth
8.08%
Trailing 12-Months
Company Description
Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Company Deck
ALKS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates a strong performance in Q3 2025, with significant revenue growth and raised financial guidance for the year. The acquisition of Avadel Pharmaceuticals is positioned as a strategic move to enhance Alkermes' portfolio and market position. While there are concerns over increased R&D and SG&A expenses, the overall outlook remains positive with promising advancements in the orexin 2 receptor agonist portfolio.View all ALKS earnings summariesALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$46.17
▲(37.74% Upside)
Technical Analysis
Ownership Overview
1.40% Insiders
28.54% Mutual Funds
0.26% Other Institutional Investors
36.93% Public Companies and
Individual Investors